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In theory, insulin resistance may result from abnormalities prior to reaching the target cell (prereceptor defects), from abnormalities at the level of the cellular receptor mediating insulin action (receptor defects), or from abnormalities within the target cell beyond the level of the reputed insulin receptor (postreceptor defects) ( Table 1) .
Amongst the prereceptor defects, the possibilities include an abnormal insulin molecule that is biologically less effective than native insulin, a case of which has recently been reported 5 ' 6 and will be discussed below; hyperproinsulinemia, in which there is failure to cleave insulin from its precursor molecule proinsulin, which has been reported in at least one family; 7 anti-insulin antibodies, which are responsible for the immunologic insulin resistance that emerges spontaneously in a rare patient and in approximately 0.01% of insulin-treated patients and is discussed by Kahn and Rosenthal in their review; 2 other circulating insulin antagonists, including hormonal antagonists (counterregulatory hormones), which may contribute to the development of diabetic ketoacidosis in spite of apparently normal circulating levels of insulin, as discussed by Schade and Eaton in their provocative review; 3 and accelerated degradation of insulin, which has been described in occasional patients receiving subcutaneous insulin 8 and may occur also as a primary cause of insulin resistance. 9 At the receptor level, insulin resistance may result from decreased receptor concentration, from a decreased affinity of insulin receptors for insulin, or from both. In addition, there have been a number of patients reported with circulating antibodies directed against the insulin receptor, 10 " 12 such as the additional case reported in this issue. 4 Most such patients have the "type B" syndrome of insulin resistance associated with acanthosis nigricans, 11 ' 12 although the patient reported by Baldwin et al. in this issue did not. 4 Decreased concentration of insulin receptors may contribute to the insulin resistance seen in obesity 13 " 15 and in nonketotic diabetes mellitus. 16 ' 17 Insulin receptor concentration is also low in uremia, 18 acromegaly, 19 and in the "type A" syndrome of insulin resistance associated with acanthosis nigricans. 11 Low receptor affinity for insulin has been reported in glucocorticoid excess 20 and lipoatrophic diabetes, 21 although the latter data are also consistent with there being two classes of insulin receptors (one with high affinity and low capacity, and another with low affinity and high capacity) in which the high affinity binding sites are absent. 22 The binding of insulin to its cellular receptor also progressively declines with decreasing pH, 23 and this may contribute to the insulin resistance associated with acute metabolic decompensation, including ketoacidosis.
The interaction between insulin and its target receptor is subject to alteration and regulation by a number of factors, the most important of which is ambient basal insulin concentration; namely, insulin regulates the concentration of its own receptor with hyperinsulinemia resulting in a decreased receptor concentration ("down-regulation"). 24 Other factors that modulate the interaction between insulin and its receptor include growth hormone, 19 glucocorticoids, 20 exercise, 25 pH, 23 and sulfonylureas. 26 Obviously, these and other potential modulators of insulin-receptor interaction must be considered in interpreting studies of the pathogenesis of insulin-resistant states. Another complicating feature is that measurement of insulin-binding sites on the cell surface, as is commonly practiced, may not be synonymous with measurement of the biologically relevant receptor for insulin action. Indeed, dissociation between insulin binding and insulin action has been demonstrated, 27 as has the presence of intracellular insulin-binding sites. 28 In addition, the most convenient and popular cell for measuring insulin receptors (or binding sites) has been the circulating monocyte, which may not be representative of insulin binding to other more biologically relevant target cells. Despite those qualifications, it appears that the conditions associated with defects observed to be at the receptor level are at least in part the result of an altered interaction between insulin and its cellular binding site.
Insulin resistance may also result from defects in insulin action within the target cell. In some types of obesity, certainly in animals and probably in human beings, insulin resistance may be a consequence of one or another intracellular defects. In uremia, too, insulin resistance may also be a consequence of an intracellular defect. 29 Better characterized as examples of insulin resistance consequent to intracellular defects are: (a) a patient with insulin resistance and acanthosis nigricans akin to the type A syndrome and termed type C in Table 1 because of its different pathophysiologic basis; 30 and (b) leprechaunism, first reported by Kobayashi et al. 31 and recently confirmed 32 to be associated with an intracellular defect in insulin action.
Characterization of the intracellular defects responsible for the insulin resistance in leprechaunism 31 " 32 and the identification of the first instance of an abnormal insulin molecule 5 * 6 represent fascinating examples of clever medical detective work. It is most instructive to review how these cases were unraveled and their biochemical mechanisms elucidated.
The first patient with leprechaunism 31 presented with glucose intolerance and marked hyperinsulinemia, suggesting insulin resistance. Insulin resistance was confirmed by the demonstration of a blunted hypoglycemic response to exogenous insulin. Prereceptor defects potentially responsible for insulin resistance were excluded by the demonstration of: (a) normal circulating insulin, indistinguishable from insulin standard in radioimmunoassay (serial dilution), gel chromatography, affinity chromatography, gel electrophoresis, and binding to specific insulin receptors on cultured IM-9 lymphocytes; (b) normal biological activity of the patient's insulin, at least in terms of normal stimulation of glucose oxidation in rat adipocytes; (c) normal proportion of proinsulin; (d) absence of anti-insulin antibodies; and (e) normal plasma levels of glucagon, growth hormone, and cortisol. Receptor defects were sought by measuring insulin binding to the patient's circulating monocytes. Both concentration and affinity were normal, although binding was at the lower end of the normal range. No antireceptor antibodies were demonstrable. A postreceptor defect was identified by showing that cultured fibroblasts obtained from the patient demonstrated normal insulin receptors but insulin failed to enhance glucose uptake above basal. This suggested to the authors that the defect was in a coupling mechanism between insulin receptors and the membrane glucose transport system.
In the other patient with leprechaunism, 32 receptor concentration as measured in postmortem liver membranes was low, whereas receptors in cultured fibroblasts were normal. The authors interpreted these findings as evidence that hyperinsulinemia had "down-regulated" the insulin receptor con-centration in vivo, whereas the absence of hyperinsulinemia in culture had permitted restoration of normal receptor concentration. In contrast, there was absence of insulin stimulation of thymidine incorporation into DNA in the patient's cultured fibroblasts, suggesting that there was an intracellular defect in insulin action. Thus, in both of the patients with leprechaunism, the various potential mechanisms for insulin resistance were systematically examined and a postreceptor defect was demonstrated.
Analogous studies were pursued in the characterization of the nature of insulin resistance in a normal weight 51-yrold man with diabetes mellitus and hyperinsulinemia. 5 Surprisingly, this patient with insulin resistance demonstrated normal responsitivity to exogenous insulin, either administered intravenously as a single bolus or infused together with glucose, propranolol, and epinephrine in a test developed by the Stanford group to quantify insulin impedance. 33 This suggested that the target cells were intact. Indeed, insulin receptors on circulating monocytes were normal, and no antireceptor antibodies were detected. Although postreceptor biological activity was not demonstrated in vitro, the normal in vivo response to exogenous insulin likely excluded a postreceptor defect. Systematic evaluation of potential prereceptor abnormalities revealed a normal proportion of proinsulin; absence of anti-insulin antibodies; and normal plasma levels of glucagon, growth hormone, and cortisol. This suggested an abnormality in insulin molecular structure. Therefore, the authors purified the insulin both from plasma and from pancreas obtained at laparotomy, 6 and this was used in testing in vitro. In comparison to insulin standard, binding to insulin receptors on cultured 1M-9 lymphocytes and rat adipocytes was only 30-50%, whereas ability to stimulate glucose transport and glucose oxidation in adipocytes was only 10-30% of controls. Thus, the patient's insulin was biologically less potent than insulin standard. Chemical analysis revealed that the extracted insulin appeared to consist of two distinct molecules, presumably the products of two allelic genes. The patient in question appeared to have a single amino acid substitution of leucine for phenylalanine at position 23 or 24 of the insulin B-chain, which is in the biologically active region of the insulin molecule.
This spectacular demonstration of a single amino acid substitution as a cause of insulin resistance is likely to stimulate further careful scrutiny of the molecular structure and biological activity of insulin in subjects with unexplained hyperinsulinemia and/or insulin resistance. Single amino acid substitutions in the insulin molecule may also occur in otherwise healthy subjects and may escape clinical detection if the substitution is away from the biologically active region of the insulin molecule. The situation may prove to be analogous to that of the hemoglobinopathies.
With such increased interest in insulin resistance and its various potential mechanisms, note should be made of the need to quantify the biological effects of insulin in vivo. Quantification of sensitivity to exogenous insulin may be carried out in several ways. The traditional clinical method is to measure the rate of glucose decrement in response to a single pulse intravenous bolus of insulin. 34 27 ' 29,37-39 j^g q Uac l rU pl e infusion method involves infusion of both glucose and insulin to achieve a steady state, while endogenous insulin is pharmacologically suppressed with epinephrine and propranolol. The "steady state plasma glucose" concentration reached at the end of the infusion is used as an index of insulin sensitivity. The "insulin clamp" technique obviates the need for pharmacological agents. In this approach, blood glucose concentration is maintained by a feedback-controlled glucose infusion after administration of physiologic amounts of insulin by constant infusion to attain an ambient insulin concentration of approximately 100 /u,U/ml. The glucose infused to maintain a constant blood glucose is a measure of glucose utilization under such conditions, and the rate of glucose infusion can thus be used as an index of tissue sensitivity to insulin. These elegant techniques permit the precise quantification of insulin effectiveness and the insulin-resistant state. Their use, in conjunction with measurements of plasma insulin levels, insulin antagonists, insulin receptors, in vitro studies of insulin action, and chemical characterization of both insulin molecules and pathways of insulin action, have already permitted an unraveling of the fundamental nature of some insulinresistant states. With the further application of these methodologies, there will clearly emerge an even better understanding of the spectrum of insulin-resistant states.
